Prognostic Value and Efficacy Valuation of Postoperative Intravesical Instillation in Primary Urothelial Carcinomas of Upper Urinary Tract

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2015 Feb 10

PMID 25663970

Citations 5

Authors

Xiaheng Deng

Xiao Yang

Yidong Cheng

Xuzhong Liu

Bian Wu

Zijie Wang

Zhengkai Huang

Kang Liu

Ruizhe Zhao

Jun Wang

Qiang Lu

Chao Qin

Changjun Yin

Affiliations

Soon will be listed here.

Abstract

Bladder tumor recurrence after surgery for upper urinary tract urothelial carcinoma (UUT-UC) is frequent. Intravesical instillation has been widely accepted as an effective way to prevent bladder tumor recurrence. We aimed to find whether postoperative instillation have benefits for bladder tumor recurrence of UUT-UC. A meta-analysis based on 6 studies from 5 publications was performed. Published literature from PubMed, EMBASE and Web of science was pooled and the hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to estimate the benefits. Conclusively, our results indicate a 62% benefit (HR = 0.38; 95% CI: 0.16-0.87) in recurrence free survival (RFS) among those treated with postoperative intravesical instillation compared with those not. Mitomycin C (MMC) and pirarubicin were found to provide more benefits than other regimens in stratified analysis. Further, after excluding one study for its heterogeneity, the results demonstrated a more reliable results of a 34% benefit (HR = 0.66; 95% CI = 0.44-0.98). This study reveals a relative benefit for postoperative instillation to improve the RFS of UUT-UC patients.

Citing Articles

[Nephroureterectomy for upper tract urothelial carcinoma : Effectiveness of single-dose intravesical chemotherapy].

Spek A Urologe A. 2020; 59(4):480-483.

PMID: 32100070 DOI: 10.1007/s00120-020-01150-8.

Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma.

Hwang E, Sathianathen N, Jung J, Kim M, Dahm P, Risk M Cochrane Database Syst Rev. 2019; 5:CD013160.

PMID: 31102534 PMC: 6525634. DOI: 10.1002/14651858.CD013160.pub2.

Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need.

Azizi M, Cheriyan S, Peyton C, Foerster B, Shariat S, Spiess P Curr Treat Options Oncol. 2019; 20(5):40.

PMID: 30937554 DOI: 10.1007/s11864-019-0637-2.

Evaluation of Intraoperative Versus Postoperative Adjuvant Mitomycin C with Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract.

Noennig B, Bozorgmehri S, Terry R, Otto B, Su L, Crispen P Bladder Cancer. 2018; 4(4):389-394.

PMID: 30417049 PMC: 6218108. DOI: 10.3233/BLC-180174.

Perioperative treatments for resected upper tract urothelial carcinoma: a network meta-analysis.

Yang X, Li P, Deng X, Dong H, Cheng Y, Zhang X Oncotarget. 2016; 8(2):3568-3580.

PMID: 27683040 PMC: 5356904. DOI: 10.18632/oncotarget.12239.

References

Witjes J, Hendricksen K . Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol. 2007; 53(1):45-52. DOI: 10.1016/j.eururo.2007.08.015. View

Hafner C, Knuechel R, Stoehr R, Hartmann A . Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer. 2002; 101(1):1-6. DOI: 10.1002/ijc.10544. View

Liu F, Liu L, Li B, Wei Y, Yan L, Wen T . p73 G4C14-A4T14 polymorphism and cancer risk: a meta-analysis based on 27 case-control studies. Mutagenesis. 2011; 26(4):573-81. DOI: 10.1093/mutage/ger018. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M . European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013; 63(6):1059-71. DOI: 10.1016/j.eururo.2013.03.032. View

Sylvester R, Oosterlinck W, Witjes J . The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008; 53(4):709-19. PMC: 2587437. DOI: 10.1016/j.eururo.2008.01.015. View

Kudoh T, Motomura F, Saitoh F, Kogawa T, Suzuki T . [Prophylactic intravesical BCG for bladder tumor after surgery of upper tract urothelial carcinoma]. Nihon Hinyokika Gakkai Zasshi. 1990; 81(12):1857-60. DOI: 10.5980/jpnjurol1989.81.1857. View

Ito A, Shintaku I, Satoh M, Ioritani N, Tochigi T, Numata I . Intravesical seeding of upper urinary tract urothelial carcinoma cells during nephroureterectomy: an exploratory analysis from the THPMG trial. Jpn J Clin Oncol. 2013; 43(11):1139-44. DOI: 10.1093/jjco/hyt129. View

Niijima T, Koiso K, Akaza H . Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol. 1983; 11 Suppl:S79-82. DOI: 10.1007/BF00256725. View

10.

Kurth K, Vijgh W, Ten Kate F, Bogdanowicz J, Carpentier P, Van Reyswoud I . Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder. J Urol. 1991; 146(6):1508-12; discussion 1512-3. DOI: 10.1016/s0022-5347(17)38152-1. View

11.

Li N, Ye Z, Na Y . Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study. Chin Med J (Engl). 2013; 126(15):2805-9. View

12.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

13.

Sylvester R, Oosterlinck W, van der Meijden A . A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004; 171(6 Pt 1):2186-90, quiz 2435. DOI: 10.1097/01.ju.0000125486.92260.b2. View

14.

Wu W, Ke H, Yang Y, Li C, Chou Y, Huang C . Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?. J Urol. 2009; 183(1):56-61. DOI: 10.1016/j.juro.2009.08.154. View

15.

Tolley D, Parmar M, Lallemand G, Benyon L, Fellows J, Freedman L . The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996; 155(4):1233-8. View

16.

Omoto T, Kano M, Ariyoshi A, Momose S, Masaki Z, Morita I . Postoperative prophylactic intravesical instillation of cytosine arabinoside and mitomycin C in superficial bladder tumor. A follow-up study. Urology. 1982; 20(5):510-4. DOI: 10.1016/0090-4295(82)90125-x. View

17.

Grossman H, Natale R, Tangen C, Speights V, Vogelzang N, Trump D . Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349(9):859-66. DOI: 10.1056/NEJMoa022148. View

18.

Sakamoto N, Naito S, Kumazawa J, Ariyoshi A, Osada Y, Omoto T . Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. Int J Urol. 2001; 8(5):212-6. DOI: 10.1046/j.1442-2042.2001.00286.x. View

19.

Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O . Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet. 1993; 342(8879):1087-8. DOI: 10.1016/0140-6736(93)92066-3. View

20.

Oosterlinck W, Kurth K, Schroder F, Bultinck J, Hammond B, Sylvester R . A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary.... J Urol. 1993; 149(4):749-52. DOI: 10.1016/s0022-5347(17)36198-0. View